Latest News

Tolebrutinib – A New Era of MS Treatments Targeting Progression in Non-Relapsing MS

May 28, 2025 | Life with MS, News, Treatments, Uncategorised

Tolebrutinib is the first and only disease modifying therapy (DMT) showing positive signs of slowing progression in non-relapsing secondary progressive MS (SPMS). While current DMTs focus on dampening the inflammatory aspects of MS, this significant breakthrough heralds a potential new […]


Wellness Practices and Complimentary Therapies

May 5, 2025 | Aids, Life with MS, Support, Symptoms, Treatments

Photo by Jared Rice on Unsplash Symptom management is an important component of living well with MS. Wellness practices or complementary therapies, can often reduce life limiting symptoms such as pain, fatigue, muscle stiffness and tightening. Certain therapies might help […]


1News Report – Medsafe Approves 10 Minute Ocrevus Injection

April 30, 2025 | Advocacy, Life with MS, Media, News, Treatments

Watch Graham Walker, person with MS, President of MS Taranaki and Co-Vice President of MSNZ discuss the life-changing news that Medsafe has approved the 10 minute Ocrevus injection, accompanied with comments from Amanda Rose, MSNZ National Manager on 1News, 29th […]


Medsafe Approves 10 Minute Ocrevus Injection; TVNZ Breakfast Interview with Graham Walker

April 29, 2025 | Life with MS, Media, Treatments

Watch Graham Walker, President of MS Taranaki and Co Vice-President of MSNZ, discuss the newly approved 10 minute Ocrevus injection with Jenny-May on TVNZ’s Breakfast show. Click here: https://youtu.be/powx9Ukm3Dw We encourage those with lived experience to provide their stories to […]


Ocrelizumab Subcut Receives Medsafe Registration as Pressure Mounts to Fund Wider Range of MS Treatment Options

April 24, 2025 | Advocacy, Life with MS, News, Treatments

Photo by Kristine Wook, Unsplash. Medsafe have approved the registration of Ocrevus ® Subcutaneous (SC) (ocrelizumab and hyaluronidase) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). The announcement on […]